NAD+ IV Therapy: Clinical Evidence & Personalization

Last reviewed: May 29, 2026

Last updated: May 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme critical for cellular energy production, DNA repair, and mitochondrial function. NAD+ levels naturally decline with age—declining approximately 50% between ages 20 and 50—and IV administration aims to rapidly restore intracellular NAD+ availability.

Interest in NAD+ IV therapy has grown as patients seek interventions that may support metabolic resilience and cellular health. Understanding the evidence, mechanism, and your own metabolic biomarkers allows you to evaluate this treatment alongside other precision-wellness strategies with clinical guidance.

How NAD+ Functions at the Cellular Level

NAD+ serves dual roles in cellular metabolism: it transfers electrons in oxidation-reduction reactions essential for ATP production and acts as a substrate for NAD+-consuming enzymes including sirtuins, PARPs, and CD38. These enzymes regulate circadian rhythm, DNA repair, inflammation, and longevity signaling pathways.

During aging and metabolic stress, intracellular NAD+ becomes depleted, potentially impairing mitochondrial efficiency and stress-response capacity. IV administration delivers NAD+ directly into circulation, theoretically bypassing oral absorption limitations and achieving higher transient plasma concentrations than oral or supplemental dosing.

NAD+ IV Administration Routes and Clinical Considerations

NAD+ IV therapy is delivered intravenously by licensed medical providers, typically in 250–500 mg doses over 15–30 minutes, with protocols ranging from single infusions to weekly or monthly regimens depending on provider framework and patient goals. Compounded or pharmaceutical-grade NAD+ preparation quality and sterility vary by provider.

Administration Factor	Clinical Consideration
Dosage range	Typically 250–500 mg IV per infusion; optimal dose not standardized in literature
Frequency	Single infusion to weekly/monthly protocols; no consensus protocol for longevity or performance
Route	Intravenous only; oral NAD+ precursors (NMN, NR) have different bioavailability profiles
Provider oversight	Requires licensed medical supervision; quality assurance depends on pharmacy and clinic standards
Peak levels	Plasma NAD+ rises acutely post-infusion; intracellular retention duration not well-defined in human studies

Current Evidence Base and Study Limitations

Published human trials on NAD+ IV therapy for longevity or age-related decline remain limited. Most evidence derives from cell culture and animal models demonstrating NAD+-dependent pathways. A small 2023 pilot study suggested NAD+ infusion may transiently improve mitochondrial function in older adults, but sample sizes are insufficient for clinical recommendations.

Observational reports and case studies describe subjective improvements in energy, fatigue, and cognitive clarity, but these lack placebo controls and standardized outcome measures. Any claims about cognitive enhancement, fatigue reversal, or anti-aging effects should be viewed as preliminary and require conversation with a qualified provider who understands the evidence gaps.

Safety Profile, Eligibility, and Provider Screening

NAD+ IV therapy is generally considered low-risk when administered by trained providers using sterile technique and pharmaceutical-grade or compounded NAD+. Reported adverse effects are uncommon and mild, including flushing, arm discomfort at infusion site, and transient nausea. Individuals with certain conditions—kidney disease, severe liver impairment, acute infection, or unstable cardiovascular status—should be screened carefully by their provider.

Before pursuing NAD+ IV therapy, discuss with your healthcare provider your current metabolic biomarkers (mitochondrial function markers, lactate, carnitine), any medications or supplements, and realistic expectations. NAD+ therapy should complement, not replace, foundational metabolic health strategies including sleep, exercise, and nutritional adequacy.

How PlexusDx Supports a More Personalized Approach

While NAD+ IV therapy targets cellular energy pathways independently of peptide signaling, PlexusDx's Precision Peptide Genetic Test may help provide context by revealing your genetic predispositions in metabolic pathways (e.g., FTO rs9939609 and MC4R rs17782313 variants). These genetic markers can inform whether your metabolic resilience profile may benefit from interventions like NAD+ therapy, metabolic support compounds, or lifestyle adjustments.

The Precision Peptide Genetic Test identifies predispositions in peptide signaling and metabolic regulation pathways, not exact responses to NAD+ therapy. However, understanding your genetic context in mitochondrial-dependent metabolic regulation—combined with your current biomarkers and health goals—can support a more personalized conversation with your provider about whether NAD+ IV therapy aligns with your precision-wellness strategy.

If you are exploring NAD+ IV therapy as part of broader metabolic optimization, integrating insights from your genetic predispositions and biomarker profile allows your provider to prioritize interventions most likely to support your individual metabolic health. This evidence-informed, personalized approach is central to precision-wellness decision-making.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $179-$229/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How long does NAD+ from a single IV infusion remain elevated in my cells?

NAD+ plasma levels rise acutely during infusion and decline within hours post-treatment. The duration of intracellular NAD+ elevation in target tissues remains unclear in human studies. Consult your provider about optimal treatment frequency based on your response.

What does current scientific evidence say about NAD+ IV therapy for aging or longevity?

Animal and cell studies suggest NAD+-dependent pathways regulate aging; however, human clinical trials on IV NAD+ for longevity are limited and preliminary. Most evidence for anti-aging claims is indirect. Any provider recommending NAD+ should acknowledge these evidence gaps.

Can I use genetic testing to determine if NAD+ IV therapy is right for me?

PlexusDx's Precision Peptide Genetic Test reveals predispositions in metabolic pathways that may contextualize your overall metabolic resilience profile. While not predictive of NAD+ response specifically, these insights can inform a broader conversation with your provider about metabolic optimization strategies.

What are potential side effects or contraindications of NAD+ IV infusion?

NAD+ IV therapy is generally well-tolerated; mild flushing, injection-site discomfort, and nausea are reported occasionally. Individuals with kidney or liver disease, infections, or unstable cardiac status should be screened carefully by their provider before treatment.

How does NAD+ IV therapy fit into a comprehensive metabolic health strategy?

NAD+ IV may serve as one component of metabolic optimization alongside sleep, exercise, and proper nutrition. If you are interested in metabolic personalization, our Precision Peptide Genetic Test can reveal genetic predispositions in metabolic pathways to support a more targeted discussion with your provider.

NAD+ IV Therapy: Biomarker Context and Provider Guidance

NAD+ intravenous therapy is a cellular energy intervention that replenishes nicotinamide adenine dinucleotide levels.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →